Literature DB >> 6629017

Control of experimental massive periretinal proliferation by daunomycin: dose-response relation.

P Wiedemann, M Kirmani, M Santana, N Sorgente, S J Ryan.   

Abstract

A condition similar to massive periretinal proliferation in man can be produced in rabbits by injecting homologous fibroblasts into the vitreous. We have studied the effect of daunomycin, a cytotoxic drug, in this model to determine a dose which would not be toxic to the retina but would be effective in preventing proliferation of the injected fibroblasts and eventual retinal detachment. The results of this study demonstrate that daunomycin at a dose of 9 nmol per eye reduces the incidence of retinal detachment by over 50%. Doses higher than 30 nmol per eye are toxic to the retina.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6629017     DOI: 10.1007/bf02308080

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  12 in total

1.  Editorial: Recent advances in vitreous surgery.

Authors:  H M Freeman
Journal:  Invest Ophthalmol       Date:  1973-08

2.  Glucocorticosteroid inhibition of intraocular proliferation after injury.

Authors:  Y Tano; D B Chandler; B W McCuen; R Machemer
Journal:  Am J Ophthalmol       Date:  1981-02       Impact factor: 5.258

3.  The role of cellular proliferation in an experimental model of massive periretinal proliferation.

Authors:  D M Fastenberg; K R Diddie; K Dorey; S J Ryan
Journal:  Am J Ophthalmol       Date:  1982-05       Impact factor: 5.258

4.  Experimental double-perforating injury of the posterior segment in rabbit eyes: the natural history of intraocular proliferation.

Authors:  T M Topping; G W Abrams; R Machemer
Journal:  Arch Ophthalmol       Date:  1979-04

5.  Mechanisms in traction retinal detachment.

Authors:  P E Cleary; S J Ryan
Journal:  Dev Ophthalmol       Date:  1981

6.  Experimental Fibroplasia in the rabbit vitreous. Retinal detachment induced by autologous fibroblasts.

Authors:  P Algvere; E Kock
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1976-05-26

7.  Treatment of intraocular proliferations with intravitreal steroids.

Authors:  R Machemer; G Sugita; Y Tano
Journal:  Trans Am Ophthalmol Soc       Date:  1979

8.  Effect of selected intravitreal drugs after severe penetrating injury in rabbits.

Authors:  S M Meyers; M M Rodrigues
Journal:  Curr Eye Res       Date:  1981       Impact factor: 2.424

9.  Inhibition of intraocular proliferations with intravitreal corticosteroids.

Authors:  Y Tano; G Sugita; G Abrams; R Machemer
Journal:  Am J Ophthalmol       Date:  1980-01       Impact factor: 5.258

10.  Fluorouracil for the treatment of massive periretinal proliferation.

Authors:  M S Blumenkranz; A Ophir; A J Claflin; A Hajek
Journal:  Am J Ophthalmol       Date:  1982-10       Impact factor: 5.258

View more
  13 in total

1.  Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment.

Authors:  D B Chandler; T Hida; S Sheta; A D Proia; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

2.  Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.

Authors:  Jay Chhablani; Alejandra Nieto; Huiyuan Hou; Elizabeth C Wu; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

3.  Experimental study on drug therapy of "traction retinal detachment" after posterior penetrating eye injury in the rabbit.

Authors:  W Behrens-Baumann; M Vogel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

4.  Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.

Authors:  Kathrin I Hartmann; Alejandra Nieto; Elizabeth C Wu; William R Freeman; Jae Suk Kim; Jay Chhablani; Michael J Sailor; Lingyun Cheng
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-28       Impact factor: 2.671

5.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

6.  Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.

Authors:  Y N Hui; H C Liang; Y S Cai; B Kirchhof; K Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

7.  Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression.

Authors:  U H Steinhorst; D L Hatchell; E P Chen; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-10       Impact factor: 3.117

8.  Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.

Authors:  Huiyuan Hou; Alejandra Nieto; Feiyan Ma; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  J Control Release       Date:  2014-01-11       Impact factor: 9.776

9.  Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit.

Authors:  M Santana; P Wiedemann; M Kirmani; D S Minckler; R Patterson; N Sorgente; S J Ryan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1984       Impact factor: 3.117

10.  Inhibition of intraocular proliferation by homoharringtonine. An experimental study.

Authors:  J P Li; C Z Hu; S Q Zeng; J M Ren; H R Wei
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1988       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.